Foetal liver infusion in a chronic myeloid leukemia patient with busulphan toxicity

1998 ◽  
Vol 15 (1) ◽  
pp. 70-71
Author(s):  
Subhadra Sharma ◽  
Vinod Kochupillai ◽  
HP Pati
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Myeloid Leukemia Patient ◽  
Leukemia Patient ◽  
Foetal Liver

Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825)

2007 ◽  
Vol 48 (12) ◽  
pp. 2461-2464 ◽  
Author(s):  
Ricardo García-Muñoz ◽  
Alicia Galar ◽  
Cristina Moreno ◽  
Paula Rodríguez-Otero ◽  
Elena Panizo-Morgado ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Parvovirus B19 ◽  
Acute Infection ◽  
Chronic Myeloid Leukemia Patient ◽  
Leukemia Patient ◽  
Herpesvirus 6

Reversal of Glanzmann thrombasthenia platelet phenotype after imatinib treatment in a pediatric chronic myeloid leukemia patient

Platelets ◽  
2017 ◽  
Vol 29 (2) ◽  
pp. 203-206 ◽  
Author(s):  
Richa Chauhan ◽  
Sudha Sazawal ◽  
Kanwaljeet Singh ◽  
R. Ragesh R. Nair ◽  
Sunita Chhikara ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Chronic Myeloid Leukemia Patient ◽  
Imatinib Treatment ◽  
Glanzmann Thrombasthenia ◽  
Leukemia Patient

Severe liver toxicity in a chronic myeloid leukemia patient probably induced by a drug interaction between imatinib and sertraline

2017 ◽  
Vol 25 (2) ◽  
pp. 484-486 ◽  
Author(s):  
Santiago Osorio ◽  
Vicente Escudero-Vilaplana ◽  
Laura Reguilón-Gallego ◽  
Ignacio Gómez-Centurión ◽  
José Luis Díez ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Liver Toxicity ◽  
Secondary Data ◽  
Hepatic Function ◽  
Chronic Myeloid Leukemia Patient ◽  
Severe Liver ◽  
Leukemia Patient ◽  
First Case

Our objective is to describe a chronic myeloid leukemia patient with a severe liver toxicity likely due to a drug–drug interaction between imatinib and sertraline. The patient started treatment with sertraline three months after starting imatinib. From the beginning of sertraline treatment, the patient developed vomiting, and five weeks later she developed a severe hepatic failure and was admitted to the hospital. The Naranjo nomogram showed a probable correlation between this adverse effect and the interaction between imatinib and sertraline. This interaction is extremely rare and the mechanism of action is not clear; it could be a mix of pharmacokinetic and pharmacodynamic processes. To our knowledge, this is the first case in medical literature of a severe liver toxicity due to an interaction between imatinib and sertraline. This interaction is also not described in the main secondary data sources, such as Lexicomp® and Micromedex®. However, due to the severity of this event, the hepatic function should be carefully monitored in patients treated with imatinib and sertraline.

Sign in / Sign up

Export Citation Format

Share Document